Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00235053 · ClinicalTrials.gov registry record · Phase 4
Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID
A Phase 4 study, sponsored by Allergy & Asthma Medical Group & Research Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 13
- Enrollment target
NCT00235053: Completed Phase 4 study, sponsored by Allergy & Asthma Medical Group & Research Center.
NCT00235053 is a Phase 4 study that has completed, run by Allergy & Asthma Medical Group & Research Center. The registered enrollment target is 13 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00235053, a Phase 4 study, has completed, sponsored by Allergy & Asthma Medical Group & Research Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 13 participants
- Enrollment target
Study Summary
This Pilot study is designed to explore the rate of local side effects of fluticasone as delivered by Advair and to determine the best outcome measure to assess these effects. This study is the initial step, and will be followed by a larger scale study.
Interventions
- DRUG fluticasone/salmeterol DISKUS 250/50
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2005-08 |
| Est. Completion | 2005-11 |
| Phase | Phase 4 |
What the finished NCT00235053 record still lists
NCT00235053 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which fluticasone/salmeterol DISKUS 250/50 is the first listed.
NCT00235053 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00235053 about?
NCT00235053 is a clinical study titled "Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID". This Pilot study is designed to explore the rate of local side effects of fluticasone as delivered by Advair and to determine the best outcome measure to assess these effects. This study is the initial step, and will be followed by a larger scale study.
What is the current status of trial NCT00235053?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 13 participants. The study started on 2005-08. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00235053?
The interventions under investigation include: fluticasone/salmeterol DISKUS 250/50 (DRUG).
Who is sponsoring clinical trial NCT00235053?
This trial is sponsored by Allergy & Asthma Medical Group & Research Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00235053's enrollment target sits among peer trials
13 1910th of 2000 higher than 88 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia